Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI105992

Production rates and metabolic clearance rates of human follicle—stimulating hormone in premenopausal and postmenopausal women

Yank D. Coble Jr., Peter O. Kohler, Charles M. Cargille, and Griff T. Ross

1Endocrinology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Coble, Y. in: PubMed | Google Scholar

1Endocrinology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Kohler, P. in: PubMed | Google Scholar

1Endocrinology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Cargille, C. in: PubMed | Google Scholar

1Endocrinology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Ross, G. in: PubMed | Google Scholar

Published February 1, 1969 - More info

Published in Volume 48, Issue 2 on February 1, 1969
J Clin Invest. 1969;48(2):359–363. https://doi.org/10.1172/JCI105992.
© 1969 The American Society for Clinical Investigation
Published February 1, 1969 - Version history
View PDF
Abstract

The production rates (PR) and the metabolic clearance rates (MCR) of human follicle—stimulating hormone (HFSH) were determined in six pre- and five postmenopausal women. Human FSH (PER-780) labeled with 131I to specific activities of 50-150 μc/μg was used as a tracer. Both double antibody and trichloroacetic acid (TCA) precipitation techniques were used to determine HFSH-131I levels in infusate and plasma. In four of the subjects MCRs measured by both constant infusion and single injection techniques were the same. By constant infusion, plasma HFSH-131I levels reached equilibrium between 4-5 hr.

MCRs in six premenopausal women were 14.2±1.1 (mean ±SE) ml/min. MCRs in five postmenopausal women were 12.6 ±1.1 ml/min. Simultaneous HFSH and human luteinizing hormone (HLH) MCRs were determined in a single patient using HFSH-125I and HLH-131I as tracers by both constant infusion and single injection methods. These studies showed that the MCR of HFSH was 10.8-11.1 ml/min, and the MCR of HLH was 18.5-19.4 ml/min. From these data and previous MCR and PR studies of HLH from this laboratory, it appears that the MCR of HFSH is about one-half that of HLH.

Endogenous HFSH and HLH levels were measured by radioimmunoassay. The PRs of HFSH, calculated by the product of endogenous level and MCR, were 146 ±27mU/min in the premenopausal women and 2141 ±264 mM/min in the postmenopausal women. 24-hr PRs, based on these results, compared with reports of 24-hr urinary excretions of biologically active HFSH indicate that 3-5% of production is found in urine in biologically active form. After our single injections of HFSH-131I, 8-29% was recovered in urine over 24 hr.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 359
page 359
icon of scanned page 360
page 360
icon of scanned page 361
page 361
icon of scanned page 362
page 362
icon of scanned page 363
page 363
Version history
  • Version 1 (February 1, 1969): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts